Intranasal Human Recombinant Modified Glucagon-Like Peptide-1: High Antihyperglycemic Activity and Duration of Action in Mice-Reference-Cited by-同舟云学术

Intranasal Human Recombinant Modified Glucagon-Like Peptide-1: High Antihyperglycemic Activity and Duration of Action in Mice

Published:2020-05 Issue:1 Volume:169 Page:53-56
ISSN:0007-4888
Container-title:Bulletin of Experimental Biology and Medicine
language:en
Short-container-title:Bull Exp Biol Med

Author:

Rykalina N. V.,Askerova E. V.,Bulushova N. V.,Kozlov D. G.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10517-020-04822-9.pdf

Reference12 articles.

1. Makarenko IE, Avdeeva OI, Vanati GV, Rybakova AV, Khodko SV, Makarova MN, Makarov VG. Possible ways of administration and standard drugs in laboratory animals. Mezdunarod. Vestn. Vetirinarii. 2013;(3):78-84. Russian.

2. Kozlov DG, Efremov BD, Sannikova EP, Klebanov FA, Cheperegin SE, Bulushova NV, Zalunin IA, Pereverzeva ER, Treshchalin ID, Yarotskij SV. Patent RU No. 2670983. Using a polypeptide derived from human glucagon-like peptide 1 as a means to control body weight. Bull. No. 31. Published October 29, 2018.

3. Petunina NA, Telnova MЕ. Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes. Sakh. Diabet. 2018;21(4):293-300. Russian.

4. Sannikova EP, Bulushova NV, Cheperegin SE, Zalunin IA, Klebanov FA, Gracheva TS, Yurin VL, Rykalina NV, Askerova EV, Yarotsky SV, Tatarnikova OG, Bobkova NV, Kozlov DG. Specific Activity of Modified Human Recombinant Glucagon-Like Peptide 1. Biotekhnologiya. 2018;34(4):37-50. Russian.

5. Sukhareva OIu, Shmushkovich IA, Shestakova EA, Shestakova MV. The incretin system in type 2 diabetes mellitus: cardiovascular effects. Probl. Endokrinol. 2012;58(6):33-42. Russian.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Agonists and Antagonists of GIP and GLP-1 Receptors: Recombinant Species-Specific Variants and Mutual Neutralization of Activity;Applied Biochemistry and Microbiology;2023-12

2. Incretin Analogues in the Therapy of Type 2 Diabetes and Obesity;Applied Biochemistry and Microbiology;2022-12

3. Copurification of a Recombinant Modified Glucagon-Like and Glucose-Dependent Insulinotropic Peptide to Create a Two-Component Drug for the Treatment of Type 2 Diabetes Mellitus and Obesity;Applied Biochemistry and Microbiology;2022-12

4. The Novel Peptide Chm-273s Has Therapeutic Potential for Metabolic Disorders: Evidence from In Vitro Studies and High-Sucrose Diet and High-Fat Diet Rodent Models;Pharmaceutics;2022-09-30

5. Co-Purification of Recombinant Modified Glucagon-Like and Glucose-Dependent Insulinotropic Peptide to Create a Two-Component Drug for the Treatment of Type 2 Diabetes Mellitus and Obesity;Biotekhnologiya;2021